 Larimar Therapeutics Inc NASDAQ: LRMR shares are trading lower despite announcing positive topline data from its Phase 1 multiple ascending dose trial evaluating CTI-1601 as a treatment for Friedreichs Ataxia FA. The data showed that repeated subcutaneous injections of CTI-1601 led to dose-dependent increases in FXN levels from baseline versus the placebo controls. 